Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
CAPR
Capricor Therapeutics Inc
$7.36
Login to see Capricor Therapeutics Inc (CAPR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Outperform the market
Chart
$6.48 (+13.58%)
$7.41 (-0.67%)
$7.66 (-3.92%)
$18.86 (-60.98%)
CAPR has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
CAPR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CAPR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CAPR Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayCAPR Earnings
The TTM reflects 12-month period, providing review of CAPR financial performance.
The company financial health has deteriorated over the past year
Financial Score
What is CAPR current stock price?
What are CAPR stock strengths?
What risks are associated with CAPR stock?
When is CAPR next earnings report?
What is CAPR market cap and volume?
What is CAPR's current Stock IQ?
Should I buy CAPR stock right now?
Is CAPR a Strong Buy right now?
What does a 'Strong Buy' rating mean for CAPR?
What does a 'Strong Sell' rating mean for CAPR?
What factors influence CAPR's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
CAPR
Capricor Therapeutics Inc
Current Price
$7.36
Stock Insights
Strengths
Earnings are forecast to grow
Outperform the market
Login to unlock Capricor Therapeutics Inc (CAPR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$6.48 (+13.58%)
$7.41 (-0.67%)
$7.66 (-3.92%)
$18.86 (-60.98%)
CAPR Analysts Opinion
CAPR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CAPR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CAPR Street view is bullish and have positive views on the near-term outlook
CAPR has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
Average key support and resistance price levels.
Login to displayCAPR Earnings
The TTM data reflects the most recent 12-month period, providing overview of CAPR financial performance.
CAPR Financial Health
The company financial health has deteriorated over the past year
Financial Score
CAPR Latest Analysis
Capricor Therapeutics Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation. SAN DIEGO Oct. 03 2025 (GLOBE NEWSWIRE) -- Johnson Fistel PLLP is investigating potential legal claims on behalf of Capricor Therapeutics Inc. (NASDAQ:) shareholders concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.Investors who have continuously held Capricor shares s
Today
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway.
Mon Sep 29, 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting. Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel the Companys investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update follows a recent Type A m
Thu Sep 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CAPR Stock trends
CAPR Stock performance
CAPR Stock analysis
CAPR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings